Overview

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the safety of Recombinant Human Coagulation Factor IX Fc Fusion Protein (rFIXFc) in previously treated pediatric subjects with hemophilia B. Secondary objectives of this study in this study population are as follows: to evaluate the efficacy of rFIXFc for prevention and treatment of bleeding episodes; to evaluate and assess the pharmacokinetics (PK) of rFIXFc; to evaluate rFIXFc consumption for prevention and treatment of bleeding episodes

Phase:

Phase 3

Details

Lead Sponsor:

Biogen
Bioverativ Therapeutics Inc.

Collaborator:

Swedish Orphan Biovitrum

Treatments:

Immunoglobulin Fc Fragments